Investment
Features
FeesSafety
Academy
More
Pluang+

Compare United States Copper Index Fund (CPER) vs Novo Nordisk A/S (NVO) Price & Performance

United States Copper Index FundTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

United States Copper Index Fund vs Novo Nordisk A/S — how do they compare? United States Copper Index Fund trades at $40.22, while Novo Nordisk A/S trades at $45.75 (market cap $207.85B). The key difference: Novo Nordisk A/S pays a 3.81% dividend while United States Copper Index Fund pays none, and United States Copper Index Fund is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.

CPERNVO
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$40.85$63.98
52-Week Low
$27.57$35.29
Market Cap
$207.85B
Enterprise Value
$222.55B
Dividend Yield
3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

United States Copper Index Fund

CPER, the United States Copper Index Fund, trades at $39.9, down 2.11% today, amid a broader bullish technical signal driven by moving averages. Recent news highlights record copper prices fueled by supply disruptions and strong demand from electrification and AI infrastructure. Key support sits at $39, with resistance at $41. Financial ratios are not applicable as this is an ETF tracking copper futures.

The outlook for CPER is positive, supported by structural copper demand trends, but carries risks from potential supply normalization and commodity price volatility. Investors gain exposure to copper's price movements without direct company fundamentals, making it a pure play on industrial metal trends influenced by global economic conditions.

Novo Nordisk A/S

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About United States Copper Index Fund

CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.

Read more on CPER

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO